Augmentin in Acute Exacerbations of Chronic Bronchitis
- 1 November 1984
- journal article
- research article
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 12 (6) , 321-326
- https://doi.org/10.1177/030006058401200601
Abstract
Forty-five patients with acute chronic bronchitis were treated with Augmentin, an amoxycillin combined with the β-lactamase inhibitor clavulanic acid, initially by parenteral administration followed by oral treatment after 3 days lasting in the mean 7·1 days. The over-all clinical evaluation showed a cure rate of 93%. Side-effects were comparable to therapy with other amoxycillins. Bacteriological evaluation of the sputum samples demonstrated in 91% of cases an elimination of the initially isolated organism. Prior to therapy we found in 25% of the isolated strains β-lactamase-producing and Augmentin-sensitive organisms. The parenteral formulation of Augmentin seems to be a valuable addition to the parenteral therapy of lower respiratory tract infections.This publication has 4 references indexed in Scilit:
- PneumologiePublished by Springer Nature ,1982
- Cinetique de l'inhibition de beta-lactamases par l'acide clavulaniqueBiochimica et Biophysica Acta (BBA) - Enzymology, 1978
- Chemical studies on the inactivation of Escherichia coli RTEM β-lactamase by clavulanic acidBiochemistry, 1978
- Kinetic studies on the inactivation of Escherichia coli RTEM β-lactamase by clavulanic acidBiochemistry, 1978